Ja nyt jatkona toukokuiseen ketjuun tuore AlzForumin AAIC-raportti donanemabista,

https://www.alzforum.org/news/conference-coverage/donanemab-data-anchors-upbeat-aaic

Piti kaivaa kaukaa aiemmista tuuttauksistani, mutta onneksi olin laittanut joitain kirjanmerkkeinä talteen.

Kuinka muut löydätte aikaisempia kirjauksianne jostain asiasta, jos haluatte jatkaa niihin sen sijaan, että aloittaisitte aina uuden ketjun?

#alzheimer #donanemab #antiamyloid #muisti #historia

Eli Lilly #drug shown to slow #Alzheimer’s progression
#Dementia experts hail "watershed moment" after trial results for #donanemab #antibody treatment showed it slowed progression by about 35% in the early stages of the disease. https://arstechnica.com/health/2023/07/eli-lilly-drug-shown-to-slow-alzheimers-progression/

"Unfortunately, these numbers do not get rid of my doubts. The clinical trial was able to demonstrate a slowing of disease progression, but it’s still not possible to say if that reaches a level that any [family member or acquaintance] would be able to notice outside of a controlled clinical trial."

The risk of these anti-amyloid drugs is real and high.

If the effect is to prolong suffering, is it really something you'd want?

#Donanemab #ALZ #Amyloid
https://www.science.org/content/blog-post/lilly-s-alzheimer-s-data-donanemab

Kyllä ei taas puutu liioittelua Ylen Riikka Kajanderin uutisjutussa läpimurrosta Alzheimer-rintamalla: https://yle.fi/a/74-20041438.

Donanemabista on raportoitu toukokuun alussa AlzForumilla, https://www.alzforum.org/news/research-news/and-then-there-were-three-donanemab-phase-3-trial-positive.

Järjestyksessä kolmas tuon tyypin tutkimuslääke, melkein floppasi 2-vaiheessa, 3. petrasi, mutta kaksi kuollutta. Jutussa ja kommenteissa lisää tietoa.

Ylen uutisen Kiviniemi on tunnettu rohkeista spekulaatioistaan mm. "aivopesun" alueella.

#alzheimer #uutisvahti #news #donanemab

A new study with more than 1700 patients finds that the drug donanemab slows down the cognitive decline due to Alzheimer's disease by about a third. While it is not a cure, it can give patients many quality years of life. See http://www.neat-news.com/2023/07/199.php. #Alzheimer #drug #donanemab

Another amyloid target drug, #Donanemab. This drug trial targeted early detection. The news (and the report) says it dramatically slowed (about 1/3rd slower progression) of ALZ. This is measured by cognitive testing. After 3 years, the group taking the drug had a ~33% lower rate of cognitive decline.

In practical terms, it means if you were projected to die in 3 years from #ALZ, you would live 1 year longer (study went 3 years, be careful to extrapolate beyond 3 yrs).

https://jamanetwork.com/journals/jama/articlepdf/2807533/jama_sims_2023_oi_230087_1689286201.27326.pdf

BBC News - Drug #donanemab seen as turning point in #dementia fight
https://www.bbc.co.uk/news/health-66221116

Just watched this really constructive discussion with top people in UK #dementia research and charities on the challenges to come over the next few years. A rare burst of positivity - and this was before the #donanemab result!
V. interesting lessons also from MS drug rollout.

Preparing for Disease Modifying Therapies for Dementia

https://www.youtube.com/live/0KoGaPzhnas?feature=share
#alzheimers #lecanemab

RT @nvillain_alz
A few thoughts on @EliLillyandCo's #donanemab Phase 3 results! Happy to debate!

https://www.alzforum.org/news/research-news/and-then-there-were-three-donanemab-phase-3-trial-positive#comment-49116

Eli Lilly &Co has announced that its new drug, #donanemab, slows the pace of #Alzheimer's by about a 1/3rd. This is the 2nd drug with promising results within a year & scientists believe after “decades of failure,” treatment for the disease is now a reality.

https://www.bbc.co.uk/news/health-65471914

RT from David Cameron (@David_Cameron)

When it comes to dementia, I often say “we need a statin for the brain”. #donanemab is not the last word in the search for a cure. But it might be the beginning of the end of this terrible condition.

My op-ed in today's @Telegraph: https://www.telegraph.co.uk/news/2023/05/04/victory-against-dementia-is-within-our-grasp/

Original tweet : https://twitter.com/David_Cameron/status/1654396217944686593

Antikörper bremst Alzheimer-Demenz. Neuer Wirkstoff Donanemab verlangsamt geistigen Abbau um im Schnitt 35 Prozent. #Alzheimer #Donanemab #Demenz #Alzheimertherapie #Antikörper
https://www.scinexx.de/news/medizin/antikoerper-bremst-alzheimer-demenz/

Today, Eli Lilly has announced positive top-line results from the TRAILBLAZER-ALZ2 Phase III #clinicaltrial of #donanemab in early #Alzheimer’s disease, which met its primary and all secondary endpoints.

We look forward to hearing more at #AAIC23.

https://www.alzheimer-europe.org/news/eli-lilly-announces-positive-top-line-results-trailblazer-alz2-trial-donanemab

Bayer’s oncology business looks to collect $10B in sales by 2030 — Some experts say FDA made the right call on Lilly's donanemab — Promising IPF treatment results sent Pliant Therapeutics stock soaring -- See more on our front page news http://bit.ly/w28kSd #bayer #oncology #prostatecancer #fda #elililly #donanemab #alzheimers #ipf #pharmanews #pharma #biotech #biotechnology #biopharma #cafepharma

The @US_FDA announced their decision not to grant accelerated approval to #donanemab for early #Alzheimer’s disease. Confirmatory Phase III trial is ongoing and @LillyPad remains on track to seek traditional approval for mid-year 2023
https://www.alzheimer-europe.org/news/us-fda-rejects-eli-lillys-application-accelerated-approval-donanemab

#FDA declines to grant accelerated approval for Eli Lilly’s experimental #Alzheimer treatment #Donanemab: https://www.cnn.com/2023/01/20/health/alzheimers-drug-donanemab-fda-eli-lilly